William Shomali

Compiled by PlainTrial · August 8, 2026

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, William Shomali sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

William Shomali: 1 sponsored US clinical trial, 1 recruiting.

William Shomali sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is JAK2 Gene Mutation, with 1 trials.

William Shomali is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 2

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

NCT03801434

Phase Distribution

Phase	Trial count
Phase 2	1

Therapeutic Areas

JAK2 Gene Mutation 1

Hypereosinophilic Syndrome 1

Hepatomegaly 1

Eosinophilia 1

Chronic Eosinophilic Leukemia, Not Otherwise Specified 1

Blasts Under 20 Percent of Bone Marrow Nucleated Cells 1

Blasts More Than 5 Percent of Peripheral Blood White Cells 1

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells 1

Blasts 20 Percent or Less of Peripheral Blood White Cells 1

BCR-JAK2 Fusion Protein Expression 1

What is open in the William Shomali pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: JAK2 Gene Mutation (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

William Shomali: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

William Shomali sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

William Shomali sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

1200 Pharma · 2 trials · 50% recruiting
1ST Biotherapeutics · 2 trials · 50% recruiting
3 Waves Wellness · 2 trials · 0% recruiting
3EO Health · 2 trials · 0% recruiting

Sponsors near 100% open enrollment (± trial volume)

AAVantgarde Bio Srl · 100% recruiting · 2 trials
Acorn Biolabs · 100% recruiting · 3 trials
Acrivon Therapeutics · 100% recruiting · 2 trials
ADARx Pharmaceuticals · 100% recruiting · 4 trials

Read our methodology - how this data is sourced, computed, and verified.

What to do with this William Shomali page

1 registered trials is a research-attention snapshot, not an endorsement of William Shomali or any single study.

1 of William Shomali's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
JAK2 Gene Mutation is the condition William Shomali studies most, compare against other sponsors active in the same condition before evaluating a specific study. See JAK2 Gene Mutation trials
Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

William Shomali pipeline card: 1 registered trials from official public datasets.Report a data error.